Table of Contents
LANGHORNE, Pa. — Insight Pharmaceuticals has acquired the Monistat feminine care North American brand portfolio from McNeil-PPC Inc.
Insight said Tuesday that vaginal antifungal brand joins its roster of over-the-counter women’s health and personal care products, which include leading brands such as e.p.t, Nix, Bonine and Sucrets.
"The acquisition of Monistat demonstrates our company’s increased presence in and dedication to the vital category of women’s health. This is a very important category to us and our retail partners and is a key part of our growth strategy going forward," stated Gary Downing, chief executive officer of Insight Pharmaceuticals. "This acquisition, along with e.p.t, has increased our revenues by nearly four times in the last 12 months."
Insight added that as part of the e.p.t transaction, it acquired the Uristat urinary pain treatment brand and is preparing to relaunch the brand.
"We are excited to bring the Uristat brand back to consumers. The acquisition of Monistat and e.p.t, the relaunch of Uristat, in addition to our vast portfolio, further defines our presence within OTC and the women’s health category," Downing commented. "Women’s health is an exciting segment, and we are eager to make an impact in this category."
Insight said Monistat will continue to be available through current retail channels and be marketed under Insight Pharmaceuticals portfolio of products.
